1. Home
  2. LGND vs SID Comparison

LGND vs SID Comparison

Compare LGND & SID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • SID
  • Stock Information
  • Founded
  • LGND 1987
  • SID 1941
  • Country
  • LGND United States
  • SID Brazil
  • Employees
  • LGND N/A
  • SID N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • SID Steel/Iron Ore
  • Sector
  • LGND Health Care
  • SID Industrials
  • Exchange
  • LGND Nasdaq
  • SID Nasdaq
  • Market Cap
  • LGND 2.3B
  • SID 2.3B
  • IPO Year
  • LGND 1992
  • SID 1997
  • Fundamental
  • Price
  • LGND $120.43
  • SID $1.73
  • Analyst Decision
  • LGND Strong Buy
  • SID Sell
  • Analyst Count
  • LGND 6
  • SID 2
  • Target Price
  • LGND $145.00
  • SID $2.95
  • AVG Volume (30 Days)
  • LGND 107.6K
  • SID 2.3M
  • Earning Date
  • LGND 11-07-2024
  • SID 11-12-2024
  • Dividend Yield
  • LGND N/A
  • SID 16.99%
  • EPS Growth
  • LGND 160.46
  • SID N/A
  • EPS
  • LGND 2.47
  • SID N/A
  • Revenue
  • LGND $152,422,000.00
  • SID $8,019,254,042.00
  • Revenue This Year
  • LGND $26.86
  • SID N/A
  • Revenue Next Year
  • LGND $13.16
  • SID $1.48
  • P/E Ratio
  • LGND $48.80
  • SID N/A
  • Revenue Growth
  • LGND N/A
  • SID N/A
  • 52 Week Low
  • LGND $67.53
  • SID $1.66
  • 52 Week High
  • LGND $129.90
  • SID $4.03
  • Technical
  • Relative Strength Index (RSI)
  • LGND 52.94
  • SID 35.29
  • Support Level
  • LGND $113.39
  • SID $1.83
  • Resistance Level
  • LGND $124.03
  • SID $1.97
  • Average True Range (ATR)
  • LGND 5.31
  • SID 0.07
  • MACD
  • LGND -0.50
  • SID -0.01
  • Stochastic Oscillator
  • LGND 48.65
  • SID 17.95

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About SID Companhia Siderurgica Nacional S.A.

Companhia Siderurgica Nacional is an integrated steel producer. The company operate throughout the entire steel production chain, from the mining of iron ore to the production and sale of a diversified range of steel products. It operates in five segments namely, Steel, Mining, Logistics, Energy, and Cement. It generates maximum revenue from the steel segment. Geographically, it derives a majority of revenue from Asia.

Share on Social Networks: